Bristol-Myers Squibb Co. (BMY) is set to face a pivotal FDA decision on March 6, 2026, regarding its supplemental New Drug Application for Sotyktu in the expanded indication of treating adults with active psoriatic arthritis.
Sotyktu (deucravacitinib), a first-in-class oral tyrosine kinase 2 (TYK2) inhibitor, was FDA-approved in September 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The drug works by selectively blocking TYK2, a key signaling enzyme mediating IL-23, IL-12, and Type I interferon pathways involved in immune and inflammatory responses.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.